Istradefilin

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Istradefilin
(IUPAC) ime
8-[(E)-2-(3,4-dimetoksifenil)vinil]-1,3-dietil-7-metil-3,7-dihidro-1H-purin-2,6-dion
Klinički podaci
Identifikatori
CAS broj 155270-99-8
ATC kod nije dodeljen
PubChem[1][2] 5311037
ChemSpider[3] 4470574
UNII 2GZ0LIK7T4 DaY
KEGG[4] D04641 DaY
ChEMBL[5] CHEMBL431770 DaY
Hemijski podaci
Formula C20H24N4O4 
Mol. masa 384,429 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Istradefilin (KW-6002) je selektivni antagonist A2A receptora. On je koristan u tretmanu Parkinsonove bolesti.[6] Istradefilin redukuje diskineziju koja je posledica dugotrajnog tretmana klasičnim antiparkinsonskim lekovima kao što je levodopa. Istradefilin je analog kofeina.

Reference[uredi | uredi kod]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD (2008). „Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)”. Annals of Neurology 63 (3): 295–302. DOI:10.1002/ana.21315. PMID 18306243. 

Spoljašnje veze[uredi | uredi kod]